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ABSTRACT
Introduction Acne is one of the most common 
inflammatory skin diseases worldwide and can have 
significant psychosocial impact and cause permanent 
scarring. Spironolactone, a potassium- sparing diuretic, 
has antiandrogenic properties, potentially reducing sebum 
production and hyperkeratinisation in acne- prone follicles. 
Dermatologists have prescribed spironolactone for acne 
in women for over 30 years, but robust clinical study 
data are lacking. This study seeks to evaluate whether 
spironolactone is clinically effective and cost- effective in 
treating acne in women.
Methods and analysis Women (≥18 years) with 
persistent facial acne requiring systemic therapy are 
randomised to receive one tablet per day of 50 mg 
spironolactone or a matched placebo until week 6, 
increasing to up to two tablets per day (total of 100 mg 
spironolactone or matched placebo) until week 24, along 
with usual topical therapy if desired. Study treatment 
stops at week 24; participants are informed of their 
treatment allocation and enter an unblinded observational 
follow- up period for up to 6 months (up to week 52 after 
baseline). Primary outcome is the Acne- specific Quality 
of Life (Acne- QoL) symptom subscale score at week 
12. Secondary outcomes include Acne- QoL total and 
subscales; participant acne self- assessment recorded 
on a 6- point Likert scale at 6, 12, 24 weeks and up to 
52 weeks; Investigator’s Global Assessment at weeks 6 
and 12; cost and cost effectiveness are assessed over 24 
weeks. Aiming to detect a group difference of 2 points on 
the Acne- QoL symptom subscale (SD 5.8, effect size 0.35), 
allowing for 20% loss to follow- up, gives a sample size of 
398 participants.
Ethics and dissemination This protocol was approved 
by Wales Research Ethics Committee (18/WA/0420). 
Follow- up to be completed in early 2022. Findings will 
be disseminated to participants, peer- reviewed journals, 
networks and patient groups, on social media, on the study 
website and the Southampton Clinical Trials Unit website 
to maximise impact.
Trial registration number ISRCTN12892056;Pre-results.
BACKGROUND
Acne vulgaris (from hereon referred to as 
acne) is the eighth most common disease 
worldwide1 and typically starts in adolescence 
with 15%–20% of people affected showing 
moderate or severe acne, often persisting into 
adulthood.2 Facial scarring occurs in approx-
imately 20% of people, but the main impact 
is social, with levels of psychological disability 
equivalent to those seen in conditions such as 
asthma and diabetes.3 4 Incidence of acne in 
adult women is considerable and growing.5–9
Strengths and limitations of this study
 ► Pragmatic design to inform real- world decision 
making for women with acne includes a primary 
outcome that is a participant- reported outcome 
measure, broad eligibility and recruitment strategies 
via primary care, secondary care, community and 
social media advertising.
 ► Randomisation to either spironolactone or matched 
placebo, with participants in both groups using top-
ical treatments as usual (creams, gels and lotions), 
if desired, in order to reflect the place of oral treat-
ments in the acne care pathway.
 ► Adaptions during the COVID-19 pandemic included 
inevitable limitations, including remote follow- up 
visits (via phone or video call), limiting collection of 
secondary outcomes such as investigator- assessed 
acne severity.  on S
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First- line treatment for acne is topical treatments either 
alone or combination preparations, containing retinoids, 
benzoyl peroxide and/or antibiotics.3 However, non- 
adherence to topical treatments is common, possibly 
because of the need to be used consistently for up to 8 
weeks, and adverse reactions, such as stinging or redness, 
are common.10 People therefore commonly seek second- 
line therapies, such as oral antibiotics, ethinylestradiol/
cyproterone acetate (co- cyprindiol) or combined oral 
contraceptives.3 In the UK, oral isotretinoin can be used 
under the supervision of a dermatologist for indications 
including severe, cystic, nodular or recalcitrant acne. 
Oral isotretinoin is highly effective, but is not suitable for 
all patients and is teratogenic,2 therefore needing careful 
pregnancy prevention management.
A third of people who consult with acne are prescribed 
long courses of oral antibiotics.3 11 However, acne is a 
disease of sebogenesis, and antibiotics have no effect on 
sebum production.12 13 Furthermore, rising rates of anti-
biotic resistance mean non- antibiotic alternatives are 
needed.14
Spironolactone, a potassium- sparing diuretic, is widely 
used in the UK for indications including hypertension15 
and has been used off- licence for women with acne 
for ≥30 years due to its antiandrogenic properties. US 
guidelines suggest a role in the management of female 
acne.1 Spironolactone is not used to treat acne in men 
because of its feminising side effects.16
There is limited evidence for the effectiveness of 
spironolactone for treating acne, and the need for 
evidence from randomised controlled trials in this patient 
group is acknowledged.16
When considering spironolactone as a potential alter-
native systemic therapy for acne, one study reported 
treatment success in women who had previously failed 
isotretinoin,17 and a second study comparing the 
frequency with which participants switched drug treat-
ment within 1 year of initiation demonstrated no signifi-
cant difference between those taking spironolactone and 
those taking oral antibiotics for their acne,18 implying they 
are equally tolerated by users. A further database study 
has shown that spironolactone may have superior drug 
usage survival compared with oral antibiotics for women 
with acne, giving a suggestion of greater perceived effec-
tiveness and tolerability.19
A James Lind Alliance Priority Setting Partnership, 
funded by the National Institute for Health Research 
(NIHR), identified the need to establish the best way 
to manage acne in women who may or may not have 
underlying hormonal abnormalities.20 This informed 
an NIHR commissioned call (16/13 persistent acne in 
adult women) for proposals to answer the research ques-
tion ‘What is the effectiveness of spironolactone in the 
treatment of moderate- severe persistent acne in adult 
women?’
This study aimed to answer whether spironolac-
tone, in addition to standard topical therapy is able to 
improve acne- related quality of life in adult women with 
moderate–severe persistent facial acne compared to 
placebo plus standard topical therapy.
METHODS
Study design and setting
The study is a phase III, multicentre, double- blind, 
randomised superiority study, to investigate clinical and 
cost- effectiveness of spironolactone in the treatment of 
moderate or severe persistent facial acne in adult women 
compared with placebo, in addition to standard topical 
treatment. The design is pragmatic in order to have 
strong external validity and to inform real- world decision 
making for women with acne and their health profes-
sionals. Pragmatic design includes broad eligibility and 
recruitment strategies, a primary outcome that is relevant 
to participants, low intensity follow- up and an intention- 
to- treat (ITT) analysis. ‘Moderate to severe acne’, in the 
context of this study, is defined as acne that warrants 
treatment with oral antibiotics, as judged by the potential 
participant and study clinician.
Baseline and follow- up appointments are carried out 
by UK hospital dermatology centres in order to facilitate 
blood tests at baseline and clinical assessments. Partici-
pants continue on the allocated treatment (spironolac-
tone or placebo) in combination with their usual topical 
treatment (if desired) for a total duration of 24 weeks 
with assessments at weeks 6 and 12. Primary outcome 
is assessed at week 12 with the patient- reported Acne- 
specific Quality of Life (Acne- QoL).21 22 From week 12, 
participants in both groups may receive ‘usual care’ from 
their usual clinical team, including oral treatments (oral 
antibiotics and hormonal treatments), and from week 
24, participants may receive isotretinoin, if the partici-
pant and study clinician feel the need for rescue treat-
ment. Trial participants receive shopping vouchers at 
baseline, 6 and 12 weeks (total £40). At week 24, partici-
pants stop taking their study treatment, are informed of 
their treatment group allocation and enter an unblinded 
observational follow- up period for up to 6 months (up to 
week 52 after baseline). During this observational final 
follow- up period, participants can ask their general prac-
titioner (GP) to be prescribed spironolactone for their 
acne if they wish or pursue other acne treatments as part 
of usual care. Figure 1 illustrates the patient pathway 
through the study with table 1 summarising the study 
procedures.
Adaptations during the COVID-19 pandemic included 
the option to hold follow- up visits at weeks 6 and 12 
remotely (phone/video calls) and to post out the study 
tablets and questionnaires to participants. Partici-
pants were also given standardised instructions on how 
to photograph their face to submit as part of remote 
follow- up assessments. Baseline visits continued to be 
face- to- face due to the requirement of a urine pregnancy 
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Participants should fulfil all the following criteria:
 ► Women aged ≥18 years.
 ► Facial acne vulgaris, symptoms present for at least 6 
months.
 ► Acne of sufficient severity to warrant treatment with 
oral antibiotics, as judged by the study clinician. 
Patients with an Investigator’s Global Assessment 
(IGA) ≥2 are eligible to participate in the study.
 ► Women of childbearing potential at risk of pregnancy 
must be willing to use their usual hormonal or barrier 
method of contraception for the first 6 months of the 
study (while taking the study investigational medic-
inal product) and for at least 4 weeks afterwards.
 ► Willing to be randomised to either study group.
 ► Willing and able to give informed consent.
 ► Sufficient English to carry out primary outcome 
Acne- QoL.
Exclusion criteria
Individuals meeting any of the following criteria will be 
excluded:
 ► Acne grades 0–1 using IGA (ie, clear or almost clear).
 ► Has ever taken spironolactone.
 ► Oral antibiotic treatment (lasting longer than a week) 
for acne within the past month.
 ► Oral isotretinoin treatment within the past 6 months.
 ► Started, stopped or changed long- term (lasting more 
than 2 weeks) hormonal contraception, ethinylestra-
diol/cyproterone acetate (co- cyprindiol) or other 
hormonal treatment within the past 3 months.
 ► Planning to start, stop or change long- term (lasting 
more than 2 weeks) hormonal contraception, ethi-
nylestradiol/cyproterone acetate (co- cyprindiol) or 
other hormonal treatment within the next 3 months.
 ► Pregnant/breastfeeding.
 ► Intending to become pregnant in the next 6 months.
 ► Contraindicated to spironolactone:
Currently taking potassium- sparing diuretic, ACE 
inhibitor, angiotensin II receptor blocker or digoxin.
Hereditary problems of galactose intolerance, lactase 
deficiency or glucose–galactose malabsorption (as 
the spironolactone and placebo tablets contain 
lactose).
Androgen- secreting adrenal or ovarian tumour.
Cushing’s syndrome.
Congenital adrenal hyperplasia.
Estimated glomerular filtration rate below 60 mL/
min/1.73 m2.
Serum potassium level above the upper limit of 
reference range for the laboratory processing the 
sample.
Intervention and control
Study participants receive one tablet per day (50 mg 
spironolactone or matched placebo) for the first 6 weeks 
of the study. At or any time after the week 6 visit, the dose 
is escalated to two tablets per day (total 100 mg spirono-
lactone or matched placebo) by the study clinician, 
providing the participant is tolerating any side effects (see 
box 1). Participants are instructed to take their total dose 
once per day in the morning to avoid diuresis later in the 
day/evening. All known adverse effects of spironolactone 
are detailed in the patient information sheet, and trial 
participants have the opportunity to discuss the trial with 
the site team and discuss any questions before consenting 
to enter the trial.
Participants may use their usual topical treatments 
throughout the study, but adherence to topicals is not 
actively promoted as this may mask differences between 
the randomised groups. Participants are discouraged 
from changing their topical treatments between baseline 
and week 12.
Figure 1 Study schem. AR, adverse reactions,
 on S
eptem









pen: first published as 10.1136/bm














































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm



































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm





6 Renz S, et al. BMJ Open 2021;11:e053876. doi:10.1136/bmjopen-2021-053876
Open access 
Intervention adherence
The hospital study team assesses participant adherence 
to treatment at each study visit using pill counts. In 
cases where only remote visits are possible, the partic-
ipant informs the study team of the number of tablets 
remaining. However, no additional support or activity 
is undertaken to encourage daily pill taking, in keeping 
with the study’s pragmatic design.
Randomisation and assignment to intervention group
Following consent, participants are randomised 1:1 by 
clinical staff at the hospital site using an independent 
web- based system (TENALEA) using varying blocks of 
size 2 and 4, stratified by centre and by baseline severity 
(IGA <3 vs 3 or more)online supplemental file 1. The 
allocation sequence was generated by a statistician using 
computer- generated random numbers. Participants, 
study staff and investigators are blind to the treatment 
allocation until the end of the treatment period at week 
24. Treatment allocation is revealed prior to week 24 only 



























































































































































































































































































































































































































































































































































Box 1 Rationale for the dosing regimen
We conducted a survey of health professionals to inform the spirono-
lactone dose regimen (unpublished). Responses were received from 41 
dermatology consultants, 10 dermatology nurses and 3 dermatology 
Specialist Registrars .
Of these 54 dermatology health professionals, 22 prescribed spi-
ronolactone (9 rarely, 10 sometimes and 3 often). Most of those who 
responded stated that they would start at 50 mg and increase up to 
100–150 mg, depending on response. Several noted that this would de-
pend on the patient’s weight, with the starting dose lowered to 25 mg if 
needed and allowing the dosage to increase up to 200 mg. There was 
no consistency on the time frame for these increases with 4, 6, 12 and 
6 months all being mentioned as review points.
A previous Health Technology Assessment study examining common 
treatments in the management of acne suggested that assessing ef-
ficacy at 6 weeks was ideal25—this informed the timing of follow- up 
assessments and dose escalation. US guidelines note that studies have 
been carried out using spironolactone doses ranging from 50 mg/day to 
200 mg/day.1 No specific dose is recommended, but it is noted that side 
effects are dose- related.1
A recent hybrid systematic review of RCTs and case series identified 
some very low- quality evidence which showed that a daily dose of 
200 mg was statistically significantly more effective than placebo ver-
sus inflamed lesions, but it also confirmed that this dose is associat-
ed with a significantly greater risk of adverse side effects than lower 
doses.17
Hence, there would appear to be no merit in using these higher doses 
for managing acne. Data from the multiple case series suggested that 
any future RCT examining lower doses is likely to generate results that 
confirm the effectiveness and better safety profile of doses of ≤100 mg/
day, which informed the dosage regimen.
For most licensed indications for spironolactone, the British National 
Formulary states a starting dose of 100 mg, titrated as required. 
Therefore, a starting dose of 50 mg in the Spironolactone for Adult 
Female Acne study seems conservative.
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Recruitment
Potential participants, identified in primary and secondary 
care, direct advertising in areas close to recruiting hospi-
tals and social media advertising, are directed to the study 
website (https://www. southampton. ac. uk/ safa) or to 
contact the local study team directly.
In primary care, recruitment is supported by general 
practices acting as participant identification centres local 
to the recruiting centres identifying potential participants 
either opportunistically or via database search based on an 
acne diagnosis and relevant prescription within the past 
6 months and mail- out of invitation pack. In secondary 
care, potential participants are identified opportunis-
tically in outpatient clinics and through screening new 
referral letters.
We use targeted social media advertising to promote 
the study, build study awareness and interest.
Participants are free to withdraw consent from the 
study at any time without providing a reason. They may 
withdraw from study treatment but remain in follow- up; 
withdraw from study and follow- up, but give permission 
for their data to be used in analyses; or completely with-
draw from the study and not permit their data to be used.
Primary and secondary outcome measures
Clinically, the effectiveness of acne treatments is usually 
judged at 8–12 weeks, so the primary outcome in the 
study is assessed at week 12 with the Acne- QoL symptom 
subscale score.21 22 The Acne- QoL was developed and vali-
dated for use in a clinical study to assess the impact of 
therapy on quality of life among people with facial acne, 
and the primary outcome at week 12 is the symptom 
subscale score of the Acne- QoL, because the Acne- QoL 
was intended to be presented as four separate subscale 
scores. It was not designed or validated to have a total 
score; however, it has published a minimum clinically 
important difference (MCID) of 2 points for the subscales 
and range 0–30 for symptom subscale score.21–23 Other 
participant- reported outcome measures in acne do not 
have a published MCID available and have not been 
found to have advantages in terms of acceptability and 
validity.24
Secondary outcomes include Acne- QoL at week 24, 
participant self- assessed overall improvement recorded 
on a 6- point Likert Scale with photographs taken at 
baseline,25 IGA,5 Participant’s Global Assessment, use of 
acne medication and participant satisfaction with study 
treatment. Trial participants are asked at each time point 
which topical or oral treatments were used in the period 
since the previous time point (if any) and have the option 
to add more information of the treatments for their 
acne in a free text box of the participant questionnaires. 
The IGA is a 5- point scale ranging from clear to severe 
(0, ‘clear’; 1, ‘almost clear’; 2, ‘mild’; 3, ‘moderate’; 4, 
‘severe’).6 26 The IGA5 25 is used to grade the participant’s 
acne as lesion counts are time- consuming, with wide 
interassessor variation and give little additional infor-
mation to global assessments. All outcome measures are 
shown in table 2.
Table 2 Schedule of observations








up (52 weeks or 
sooner)‡‡
Primary outcome measure
Acne- QoL symptom subscale score X
Secondary outcome measures
Acne- QoL symptom subscale score X X X X
Acne- QoL other subscales X X X X
Acne- QoL total score* X X X X
Participant self- assessed overall improvement† X X X X
IGA‡ X X
Participant’s Global Assessment§ X X X X
Participant satisfaction with study treatment¶ X
Health- related quality of life using EQ- 5D- 5L** X X X X
Costs incurred X X X X
Cost- effectiveness†† X
*Self- perception, role—emotional and role—social.
†Recorded on a 6- point Likert Scale with photographs taken at the baseline visit to aid recall.37
‡5- point scale ranging from clear to severe (0, clear; 1, almost clear; 2, mild; 3, moderate; 4, severe).25
§Same scale as the IGA but written in plain English for participants’ use.
¶Asked prior to revealing treatment allocation after 24 weeks.
**The EQ- 5D-5 L assesses five dimensions: mobility, self- care, usual activities, pain/discomfort and anxiety/depression.
††Using EQ- 5D- 5L and data on health resource use during the study.
‡‡The follow- up questionnaire will be sent out 6 months or sooner after the 24- week time point.
IGA, Investigator’s Global Assessment.
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The safety profile of spironolactone is well estab-
lished.15 16 Consequently, we collect information about 
adverse reactions of special interest, both to inform the 
dose review decision from week 6 onwards as well as to 
learn more about incidence of side effects in this popula-
tion. We also collect and report all serious adverse events 
(SAEs).
Pregnancy
Spironolactone is considered contraindicated in preg-
nancy or a category C drug (ie, potential benefits may 
warrant use in pregnant women despite potential 
risks).1 15 The main concern is around possible feminisa-
tion of the male fetus in the third trimester of pregnancy.1 
Women of childbearing potential at risk of pregnancy will 
be asked to use their usual hormonal or barrier method 
of contraception during the first 24 weeks of the study 
and for at least 4 weeks (approximately one menstrual 
cycle) afterwards. A pregnancy test will be conducted for 
all participants at their baseline visit and documented in 
their medical notes. At weeks 6 and 12, the study nurse/
doctor will ask participants to confirm that they are still 
using contraception and have not changed their contra-
ceptive method. Participants who become pregnant will 
be asked to inform their local site study team as soon as 
possible and will not be able to continue in the study.
Sample size
Based on comparison of the Acne- QoL symptom score 
between groups at week 12, power 90%, alpha 0.05 and 
seeking a difference between groups of 2 points on the 
symptom subscale (SD 5.8, effect size 0.35), 346 partici-
pants are needed. Allowing for 20% loss to follow- up gives 
a total 434 participants (217 per group). Following discus-
sions with oversight committees postfunding award, the 
sample size was recalculated. Allowing for a correlation 
with baseline of 0.293 and a deflation factor of 1-ρ227 gives 
a total sample size required of 398 participants. A differ-
ence of 2 points on the symptom subscale and an SD of 
5.8 (equivalent to an effect size 0.35) is in line with that 
reported in studies in a similar patient group and with the 
MCID reported for Acne- QoL.21 22
Data collection methods
Participant data are entered into study electronic case 
report forms (eCRFs) via a remote data collection tool 
(Medidata Rave) by trained hospital research personnel 
with specific roles on the study and are regularly checked 
for missing or anomalous values by the Southampton 
Clinical Trials Unit (CTU) study staff.
Data management
Participant data are pseudonymised by assigning each 
participant a participant identifier code, which is used 
to identify the participant during the study and for any 
participant- specific communication between South-
ampton CTU and recruiting sites. The site retains a 
participant identification code list which is only available 
to site staff and stored in a secure location at site.
Patient and public involvement (PPI)
This study addresses a priority area identified as important 
to patients and health professionals by the James Lind 
Alliance Priority Setting Partnership for Acne.7 We 
gained feedback from a virtual acne- specific patient 
panel, convened through ‘People in Research’ (https://
www. peopleinresearch. org). A patient survey was carried 
out with the support of the UK Dermatology Clinical 
Trials Network in order to inform the study design. Find-
ings suggested that participants would find it difficult to 
abstain from using topical treatments for more than 12 
weeks and that asking participants to take a placebo for 
1 year would also be a barrier to recruitment.
Two public contributors with experience of acne attend 
all Trial Management Group (TMG) meetings to ensure 
that decisions around the study design are informed by 
their perspective; study procedures are feasible for partici-
pants, and study materials are readable and include all the 
relevant information that participants would want. Public 
contributors influenced the trial design and delivery, for 
instance, by advocating use of social media advertising to 
improve recruitment, arguing against repeated measures 
in this patient group and that an upper age limit of 50 
years was arbitrary and could appear discriminatory.
Statistical methods
The study will be reported in accordance with Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines. A detailed statistical analysis plan (SAP) will be 
written and reviewed prior to the study database being 
locked.
The modified ITT population consists of all partici-
pants who have consented and have been randomised to 
a treatment arm and have complete data for the outcome 
being analysed. Analyses will be performed according 
to the modified ITT principle using a linear regression 
model. All analyses will be carried out in the modified 
ITT population, with the level of missing data reported, 
unless otherwise stated. The frequency and pattern of 
missing data will be examined and a multiple imputation 
model will be used as a sensitivity analysis if appropriate.
For the primary analyses, descriptive statistics will be 
obtained for the randomised groups to characterise 
recruited participants and assess baseline comparability. 
For the primary outcome, a linear regression model will 
be used to analyse Acne- QoL symptom subscale at week 
12, adjusting for baseline variables (including baseline 
Acne- QoL symptom subscale score, use of topical treat-
ments, use of hormonal contraception/ethinylestradiol/
cyproterone acetate (co- cyprindiol) and randomisation 
stratification variables (centre, baseline severity (IGA <3 
vs 3 or more)). A full list of covariates and model speci-
fication will be set out in the SAP. A 95% CI for the least 
squares mean difference between arms in Acne- QoL 
symptom subscale at week 12 will be calculated.
The same analysis methods will be used to summarise 
Acne- QoL symptom subscale at other time points (weeks 
6, 24 and up to week 52 after baseline) and for the other 
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Acne- QoL subscales (self- perception, role—emotional 
and role—social) and total score. IGA and participants’ 
comparison with baseline photo at weeks 6, 12 and 24 will 
be dichotomised as success or failure as recommended by 
the US Food and Drug Administration (with success for 
IGA and Participant’s Global Assessment defined as clear or 
almost clear (grade 0 or 1) and at least a two- grade improve-
ment from baseline; this represents a clinically meaningful 
outcome). The dichotomised outcomes will be summarised 
by frequencies and percentages and compared by group 
using logistic regression, adjusting for baseline assessment, 
use of hormonal contraception/ethinylestradiol/cypro-
terone acetate (co- cyprindiol), use of topical treatment and 
randomisation stratification factors.
Adverse reactions of special interest and SAEs will be 
summarised by group with frequencies and percentages 
and compared with Pearson’s χ² tests. Logistic regression 
modelling will also be used to adjust for any important 
differences in topical treatment use by group. Subgroup 
analyses will investigate how the treatment effect differs by 
whether participants have symptoms consistent with poly-
cystic ovary syndrome as recorded at the baseline visit. It is 
acknowledged the study is not powered for this subgroup 
analysis. The same analysis methods will be applied to the 
outcomes collected at up to 52 weeks; however, the inter-
pretation of these results will be assessed with caution as 
participants will potentially have been off treatment for up 
to 6 months or have started a different acne treatment. All 
analyses will be carried out using Stata and/or SAS.
There are no planned interim analyses or subgroup 
analyses.
Health economics analysis
If the intervention is found effective, a within- study 
economic evaluation will be undertaken to assess value for 
money of spironolactone plus usual care versus placebo 
plus usual care. The main perspective of the analysis will 
be that of the NHS over the 24- week treatment period, 
although a secondary analysis will assess the importance 
of a broader perspective by incorporating out- of- pocket 
costs related to acne and any productivity/employment 
impacts for people with persistent acne.28
Costs, including intervention and wider NHS resource 
use, are being recorded in the study eCRF for the former, 
while wider NHS resource use is captured in participant 
questionnaires at baseline and weeks 6, 12 and 24.
Costs will be valued using published unit costs for a 
common recent price year to estimate mean cost per 
participant in each arm.29–31
Review of the reliability, validity and responsiveness 
of three generic preference- based measures (EQ- 5D, 
Short- Form Six Dimensions (SF- 6D) and Health Utilities 
Index (HUI)) in skin conditions only found evidence 
to support the use of the EQ- 5D in skin diseases with 
no studies looking at measurement properties for the 
SF- 6D or HUI in skin disease.32 Problems on the EQ- 5D 
domains were found to be substantially higher in the acne 
sample receiving specialist care than in an age- truncated 
population sample (aged 20–39 years) particularly on the 
pain/discomfort (42.1% in the acne sample vs 17.7% in 
an age- truncated population sample) and anxiety/depres-
sion domains (52.8% vs 12.5%, respectively).33 EQ- 5D was 
found to be responsive to change, with moderate effect 
sizes at 4 and 12 months (−0.44 and −0.53, respectively).33 
We will value the EQ- 5D- 5L in our primary analysis in line 
with NICE recommendations at the time of analysis.3 34 
Quality- adjusted life years (estimated using EQ- 5D- 5L32 33) 
for the study period will be estimated using linear inter-
polation and area under the curve with and without 
baseline adjustment.35 Clinical measures were found to 
be more responsive to change than the generic measures 
(shown by larger effect sizes), and combination of generic 
preference- based measures with the use of disease specific 
measure was concluded to be desirable.33 The primary 
economic evaluation will be an incremental cost utility 
analysis to enable the cost effectiveness to be compared 
across a range of health conditions and interventions such 
that decision makers can use the information to inform 
prioritisation of healthcare. A secondary cost effective-
ness analysis using the disease- specific Acne- QoL will be 
presented as appropriate, though it should be noted that 
this instrument does not have utility weights available and 
it is unclear what incremental cost per unit of change on 
the Acne- QoL represents good value for money. All anal-
yses will be conducted and presented using established 
methods.28 36
If spironolactone is not found to be clinically effective, 
a full economic evaluation will not be conducted. Instead, 
estimates of mean costs and utility per participant will be 
presented at the various study time points as these may 
be informative for other researchers undertaking future 
economic studies or economic modelling in this clinical 
area.
A detailed health economic analysis plan will be written 
prior to the study database being locked.
Oversight and monitoring
The TMG includes representatives with expertise in 
dermatology, primary care research, psychology, medical 
statistics and health economics, public contributors, 
and Southampton CTU staff involved in the day- to- day 
running of the study and is responsible for the oversight 
of the progress of the study. An independent trial steering 
committee and an independent data monitoring and 
ethics committee have been set up to monitor study prog-
ress and safety.
Data on adverse reactions will be collected at the 
baseline and follow- up visits, and participants will be 
asked to report any adverse reactions in their week 24 
questionnaire. SAEs may be identified by participant 
report at any time directly to the hospital study team, at 
follow- up visits or questionnaires. Participants’ GPs will 
be informed of their patient’s participation in the study 
and will be asked to notify the hospital study team of 
any potential SAE. The study also has a UK regulatory 
compliant real- time SAE reporting process to identify 
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serious adverse reactions and suspected unexpected 
serious adverse reactions that could suspend or stop the 
study if warranted.
The Southampton CTU has undertaken a risk assess-
ment for the study, which includes the requirements for 
monitoring (both central and site). The Southampton 
CTU undertakes a number of internal audits of its own 
systems and processes annually and has routine audits 
from both its sponsor and the independent Medicine 
and Healthcare Products Regulatory Authority every 2–3 
years.
DISCUSSION
This is the first adequately powered pragmatic, randomised 
trial investigating the effect of spironolactone on acne 
in adult women in comparison to a matched placebo. If 
found to be clinically effective and cost effective, use of 
spironolactone will likely become the new standard of 
care in addition to topical treatments potentially reducing 
antibiotic use for women requiring systemic therapy.
Respondents to a survey of people with experience 
with acne reported that they would be unwilling to be 
recruited to a study where they remained blinded to the 
treatment allocation for 52 weeks, due to concerns about 
potential worsening of acne over this time. Therefore, the 
study was designed as blinded treatment phase of 24 weeks 
with an observational follow- up period for up to 6 months 
after. Use of acne treatments, such as oral isotretinoin or 
antibiotics, between week 24 and up to week 52 are care-
fully recorded as differences between groups and would 
be important in interpreting week 52 outcomes. Use of 
topical treatments is allowed in both groups during the 
24- week treatment phase as (1) women with moderate–
severe acne may be unwilling to be randomised to placebo 
alone, and (2) recruiting women with moderate–severe 
acne to a placebo- controlled study with no effective treat-
ment for 12 weeks in the control arm may risk worsening 
of acne and possible scarring.
Although others are seeking to evaluate the role of 
spironolactone in comparison with oral tetracyclines,37 
this is the largest study to date to inform clinical practice 
over the effectiveness of spironolactone as an alternative 
treatment for acne in adult women.
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